

AD-A274 309



AD _____

(2)

CONTRACT NO: DAMD17-93-C-3004

**TITLE: PRECLINICAL PHARMACODYNAMIC AND PHARACOKINETIC STUDIES
OF INVESTIGATIONAL NEW DRUGS**

PRINCIPAL INVESTIGATOR: Dr. Patricia Noker

**CONTRACTING ORGANIZATION: Southern Research Institute
2000 Ninth Avenue South
P.O. Box 55305
Birmingham, Alabama 35255-5305**

REPORT DATE: November 11, 1993

TYPE OF REPORT: Annual Report

**PREPARED FOR: U.S. Army Medical Research and
Development Command, Fort Detrick
Frederick, Maryland 21702-5012**

**DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited**

**S DTIC
ELECTE
DEC 27 1993
A**

**The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.**

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED
11 November 1993 Annual Report (11/2/92-10/31/93)

4. TITLE AND SUBTITLE 5. FUNDING NUMBERS
Preclinical Pharmacodynamic and Pharmacodynamic Contract No.
and Pharmacokinetic Studies of Investigational DAMD17-93-C-3004
New Drugs

6. AUTHOR(S)
Dr. Patricia Noker

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION
Southern Research Institute REPORT NUMBER
2000 Ninth Avenue South SRI-BIO-93-941
P.O. Box 55305
Birmingham, Alabama 35255-5305

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING/MONITORING
U.S. Army Medical Research & Development Command AGENCY REPORT NUMBER
Fort Detrick
Frederick, Maryland 21702-5012

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE
Approved for public release; distribution unlimited

13. ABSTRACT (Maximum 200 words)

93 12 23 078 93-31233



14. SUBJECT TERMS 15. NUMBER OF PAGES
Pharmacokinetics, Drugs, lab animals, RAD I, V

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT 18. SECURITY CLASSIFICATION OF THIS PAGE 19. SECURITY CLASSIFICATION OF ABSTRACT 20. LIMITATION OF ABSTRACT
Unclassified Unclassified



Southern Research Institute

November 11, 1993

**LTC Moshe Shmuklarsky, M.D.
Walter Reed Army Institute of Research
ATTN: SGRD-UWM-C
Forest Glen Annex
Washington, D.C.**

**Reference: Contract No.: DAMD17-93-C-3004
Subject: Annual Report
Contractor: Southern Research Institute
Principal Investigator: Dr. Patricia E. Noker
Telephone No.: (205) 581-2335
Period Covered: 2 Nov 1992 - 31 Oct 1993
SRI Report No.: SRI-BIO-93-941**

Dear Dr. Shmuklarsky:

The following is a listing of the activities performed under this contract during the above referenced contract year:

1. Under Task Order 92-01, a protocol and a cost estimate for the performance of a pharmacokinetic and metabolism study of sodium artelinate (WR255663) in rats were prepared and submitted to the COR. This study was, however, postponed for an unspecified period of time due to lack of appropriate funding.

2. Task Order 93-02, which entails the performance, in dogs, of a pharmacokinetic, bioavailability and metabolism study of WR242511, an agent proposed as a cyanide pretreatment/prophylactic drug, was issued. Validation of the analytical methods to be used during the study was initiated in October. To date, no reportable data are available.

3. Under Task Order 93-03, a protocol was prepared for the performance, in dogs, of a pharmacokinetic and metabolism

Southern Research Institute

**LTC Moshe Shmuklarsky
Walter Reed Institute**

**Page 2
November 11, 1993**

study of HI-6 (WR249655), a compound which is under consideration as a nerve agent antidote. A request for a cost estimate for the performance of this study is pending.

Sincerely,

Patricia E. Noker

**Patricia E. Noker, Ph.D.
Head, Biochemical Pharmacology**

Approved by:

Donald L. Hill
**Donald L. Hill, Ph.D.
Director, Biochemistry Research**

DTIC QUALITY INSPECTED 5

Accession For	
NTIS	ORPNI
DTIC	1A6
Unannounced	
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	